Project Grant R43DK136496
Award Date
8/4/23
Completion Date
8/3/24
Dollars Obligated
$298K
Similar Awards
This $310,897 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a first-in-class, islet-targeted antibody therapeutic for Type 1 Diabetes (T1D). The award supports preclinical development and validation activities for this novel antibody therapy, including establishing proof-of-principle for its islet-homing capability, therapeutic...
The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...
This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,108,154 to develop a stem cell-based multi-cellular platform that integrates diverse types of immune cells with stem cell-derived islets. The goal is to create an improved preclinical research model to accelerate the development of therapeutic interventions for Type 1...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is focused on enhancing the metabolic maturity of human pluripotent stem cell-derived islet organoids for improved transplantation outcomes in type 1 diabetes. The $681,562 award, granted on July 21, 2025, will support research at the University of Michigan to investigate pharmacological and 3D...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support the development of a tolerogenic nanotherapy to delay the onset of Type 1 Diabetes (T1D). The $350,000 award to SNC Therapeutics, Inc. will be used to optimize the dosing of their rapamycin-loaded polymersomes (RPS) and scale up the polymer synthesis and RPS formulation, with the goal...
This Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $132,270 to the University of Florida to develop a multi-functional biomaterial scaffold that improves the vascularization, engraftment, and immunoprotection of transplanted pancreatic islets for the treatment of type 1 diabetes. The key objectives are to: 1) Identify specific scaffold...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $208,428 to The Regents of the University of California, San Francisco (UCSF) to enhance the safety and efficacy of stem cell-derived islet transplantation for treating type 1 diabetes. The key focus is on utilizing CRISPR-mediated genome engineering to improve islet cell engraftment,...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...
This Project Grant award of $199,258 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to The Leland Stanford Junior University will fund research to develop reduced-intensity conditioning regimens to induce sustained mixed hematopoietic chimerism and tolerance for islet cell transplantation in type 1 diabetes. The research aims to 1) optimize a low-intensity conditioning protocol to reduce the radiation dose required for generating mixed chimerism, and 2)...